Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can zapping all spots of prostate cancer delay progression? PLATON trial aims to find out

NCT ID NCT03784755

Ongoing Disease control Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial is testing whether adding local ablative therapy (radiation or surgery) to all visible cancer sites, on top of standard hormone therapy, improves outcomes for men with hormone-sensitive prostate cancer that has spread to a few spots (oligometastatic). About 409 men with up to 5 metastases are being randomly assigned to receive either standard care alone or standard care plus ablative therapy. The main goal is to see if this approach delays cancer progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ablative radiation therapy (SBRT) or surgery
What this could lead to
If successful, this could show that treating all visible cancer spots with radiation or surgery, alongside standard hormone therapy, delays cancer progression better than standard therapy alone.
What could go wrong
This is an active but not recruiting phase 3 trial, so results are not yet available. Adding local therapy may not improve outcomes and could cause side effects from extra radiation or surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER METASTATIC

Contacts and locations

Locations

  • Algoma District Cancer Program

    Sault Ste. Marie, Ontario, P6B 0A8, Canada

  • Allan Blair Cancer Centre

    Regina, Saskatchewan, S4T 7T1, Canada

  • BCCA - Victoria

    Victoria, British Columbia, V8R 6V5, Canada

  • CHUM-Centre Hospitalier de l'Universite de Montreal

    Montreal, Quebec, H2X 3E4, Canada

  • CIUSSS de l'Est-de-I'lle-de-Montreal

    Montreal, Quebec, H1T 2M4, Canada

  • CancerCare Manitoba

    Winnipeg, Manitoba, R3E 0V9, Canada

  • Health Sciences North

    Greater Sudbury, Ontario, P3E 5J1, Canada

  • Hotel-Dieu de Quebec

    Québec, Quebec, G1R 2J6, Canada

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, L8V 5C2, Canada

  • Kingston Health Sciences Centre

    Kingston, Ontario, K7L 2V7, Canada

  • Odette Cancer Centre

    Toronto, Ontario, M4N 3M5, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, K1H 8L6, Canada

  • QEII Health Sciences Centre

    Halifax, Nova Scotia, B3H 1V7, Canada

  • Royal Victoria Regional Health Centre

    Barrie, Ontario, L4M 6M2, Canada

  • Saskatoon Cancer Centre

    Saskatoon, Saskatchewan, S7N 4H4, Canada

  • The Jewish General Hospital

    Montreal, Quebec, H3T 1E2, Canada

  • Trillium Health Partners - Credit Valley Hospital

    Mississauga, Ontario, L5M 2N1, Canada

  • University Health Network

    Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.